Locally advanced/late/recurrent or metastatic solid tumors
Conditions
Interventions
Observation group:None
Sponsors
The First Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Signed informed consent form and voluntarily joined this study; 2. Patients with histologically or cytologically confirmed solid tumors of the following: (1) Extensive-stage small cell lung cancer; (2) Patients with advanced solid tumors other than the above-mentioned histologically or cytologically confirmed tumor types, if the investigator believes that the patient may benefit from the choice of adebelimab based on the currently known data, may also be considered for enrollment; 3. Age>=18 years old; 4.The investigator determines that the patient can be treated with adebelimab.
Exclusion criteria
Exclusion criteria: 1. evidence that the patient is a pregnant or lactating female; 2. the patient is receiving a treatment regimen in a blinded trial; 3. other conditions that, in the judgment of the investigator, make inclusion in the study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of treatment-related adverse reactions;Incidence of serious adverse events;Incidence of immune-related adverse reactions;Management and outcomes of immune-related adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient demographics and clinical characteristics;Treatment mode; | — |
Countries
China
Contacts
Public ContactYusheng Wang
The First Hospital of Shanxi Medical University
Outcome results
None listed